Adjunctive CADx aid for interpreting OB-GYN/MFM physicians to identify suspicious fetal-cardiac findings in second-trimester anatomic ultrasound that may suggest congenital heart defects and inform the need for additional exams.
Evidence status: each field shows source quality, applicability, and review date. Research pending, information not established in reviewed sources, and vendor documentation pending are distinct outcomes.
Clinical fit
What this tool is for
Start with the authorized purpose, then verify how it fits your service line and reading workflow.
Exact purpose
Adjunctive CADx aid for interpreting OB-GYN/MFM physicians to identify suspicious fetal-cardiac findings in second-trimester anatomic ultrasound that may suggest congenital heart defects and inform the need for additional exams.
FDA source Exact FDA submission Checked 2026-09-08
Second-trimester fetal anatomic ultrasound, typically 18-24 weeks, in an obstetric imaging workflow; pregnant women are aged 18 or older and facility type is not specified.
FDA source Exact FDA submission Checked 2026-09-08
Concurrent reading aid for detection and assessment of suspicious fetal-cardiac findings; physician review and standard diagnostic testing remain primary.
FDA source Exact FDA submission Checked 2026-09-08
Cardiac fetal ultrasound video clips containing interpretable 4-chamber, left-ventricular-outflow-tract, and right-ventricular-outflow-tract standard views from second-trimester exams.
FDA source Exact FDA submission Checked 2026-09-08
For each frame, each finding is assessed as present, absent, or inconclusive; record-summary tables summarize each video clip and exam-summary tables summarize the overall study for overriding artery, cardiac-crux septal defect, abnormal outflow-tract relationship, enlarged cardiothoracic ratio, ventricular-size discrepancies, valve-annular-size discrepancies, and cardiac-axis deviation.
FDA source Exact FDA submission Checked 2026-09-08
Adjunct only; it does not replace the physician or other diagnostic testing. It is not intended for multiple pregnancies, heterotaxy, or postnatal ultrasound exams. The packet states validation and intended use only with Fujifilm, GE, Philips, Samsung, and Toshiba ultrasound devices.
FDA source Exact FDA submission Checked 2026-09-08
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
FDA submission
K242342
FDA source Exact FDA submission Checked 2026-08-31
Use these fields to structure a vendor demo, security review, and implementation estimate.
Integration
Cloud-based software-only processing of fetal ultrasound video clips is described. Exact DICOM, PACS, RIS, EHR, transfer, and routing interfaces are not established by the packet; the packet names the validated/intended ultrasound vendors.
FDA source Exact FDA submission Checked 2026-09-08
Public source Exact FDA submission Checked 2026-08-13
Deployment category preserved from the prior exact-submission review; hosting region, data flow, and current commercial configuration still require vendor confirmation.
Vendor confirmation Exact FDA submission Checked 2026-09-08
Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
Training and support
Vendor documentation pending
Vendor confirmation Exact FDA submission Checked 2026-09-08
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring and change control
Vendor documentation pending
Vendor confirmation Exact FDA submission Checked 2026-09-08
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
ACR exact-submission catalog context
ACR AI Central provides an exact-submission model card for Fetal EchoScan; FDA labeling remains controlling for clinical use, limitations, and performance.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version.
Evidence summary
FDA K242342 reports standalone testing on 877 clinically acquired second-trimester fetal ultrasound exams from 11 centers, with 98.8% of exams producing a conclusive output. For any suspicious finding, sensitivity/specificity were 0.977/0.977 when inconclusive outputs were counted negative and 0.987/0.963 when counted positive, with separate per-finding results. A distinct fully crossed MRMC reader study used 200 exams and 14 readers: aided AUC was 0.974 versus unaided 0.825, aided mean sensitivity was 0.935 versus 0.782, and aided mean specificity was 0.970 versus 0.759.
FDA source Exact FDA submission Checked 2026-09-08
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Fetal EchoScan regulatory performance study summary
Stand-alone performance and reader study (ACR AI Central category) · Adult
exact submission · Tested version: Exact product version not reported; regulatory study summarized for FDA submission K242342 · n=877 · 11 sites · Independence not established
K242342
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
These are common procurement questions; unknown values remain visible until a source supports them.
Pricing and total cost
Vendor documentation pending
Vendor confirmation Exact FDA submission Checked 2026-09-08
No public price or quote for the exact K242342 configuration was established in this review.
Reimbursement and coding
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-08
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Safety and lifecycle
Postmarket record
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K242342. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
Public source Exact FDA submission Checked 2026-09-08
Verify security and privacy controls: Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
Verify training: Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Verify pricing and total cost: No public price or quote for the exact K242342 configuration was established in this review.
Verify reimbursement and coding relevance: No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Verify local validation and lifecycle monitoring: Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-08Last searched
23Fields reviewed
9Source classes checked
0Unreviewed PubMed leads
0Unreviewed trial leads
0Unreviewed FDA recall leads
Exact-submission ACR model-card fields were normalized under the current provenance rules; vendor and independent-study confirmation remain distinct. Exact FDA scope controls clinical claims. ACR provides bounded exact-submission catalog context. Candidate literature metadata remains a discovery queue until full-text identity, endpoint, population, and version review is completed. Automated exact-name discovery found 0 PubMed and 0 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads remain unpublished until a human confirms the exact product and tested version.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
FETOLY analyzes fetal ultrasound images and sequences to detect labeled fetal brain and heart views, assess image completeness or quality, and provide fetal biometric measurements...
Adjunctive detection of suspicious fetal cardiac findings during second-trimester ultrasound to aid concurrent OB-GYN or maternal-fetal-medicine interpretation.
Modality
Ultrasound
Anatomy
Fetal heart, including four-chamber, left-ventricular-outflow-tract, and right-ventricular-outflow-tract views and the specified suspicious cardiac findings